Do you face challenges when it comes to the particle quality in your granulation process? In order to produce granules with the desired properties, scale-up is crucial, in addition to looking at the process parameters. After all, the path of a drug from the laboratory to production holds many a surprise. Especially in the case of particles for inhalers, the mixing process plays a decisive role.
Learn what you need to consider to produce the perfect particle. This whitepaper reveals expert know-how on the mixing details, the key figures to consider and the positive effects using the practical example of inhalants.
In October, FDA reorganized rare disease development around a fit-for-purpose framework and a new pathway for individualized gene editing. Regulators in Europe and the UK set out long-term plans for clinical trials, AI, and moving away from animal testing.
Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
The FDA approves VOCERYQ, the first DNA medicine, for RRP surgery reduction, raising plasmid, drug-device, and confirmatory trial manufacturing demands.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
